Maria Grano

List of Publications by Year
in descending order

165 papers	8,253 citations	44444 50 h-index	64407 83 g-index
169 all docs	169 docs citations	169 times ranked	8961 citing authors

#	Article	IF	Citations
1	Antibody Treatment and Osteoporosis: Clinical Perspective. Springer Series in Biomaterials Science and Engineering, 2022, , 111-126.	0.7	0
2	Irisin and Secondary Osteoporosis in Humans. International Journal of Molecular Sciences, 2022, 23, 690.	1.8	21
3	Irisin Serum Levels and Skeletal Muscle Assessment in a Cohort of Charcot-Marie-Tooth Patients. Frontiers in Endocrinology, 2022, 13, .	1.5	10
4	Antidepressant Effect of Intermittent Long-Term Systemic Administration of Irisin in Mice. International Journal of Molecular Sciences, 2022, 23, 7596.	1.8	11
5	Capsid-like biodegradable poly-glycolic acid nanoparticles for a long-time release of nucleic acid molecules. Materials Advances, 2021, 2, 310-321.	2.6	9
6	In Vivo and for the Study of Bone Remodeling and the Role of Immune Cells. Methods in Molecular Biology, 2021, 2325, 97-106.	0.4	0
7	FNDC5/Irisin System in Neuroinflammation and Neurodegenerative Diseases: Update and Novel Perspective. International Journal of Molecular Sciences, 2021, 22, 1605.	1.8	61
8	The genetic background and vitamin D supplementation can affect irisin levels in Praderâ€“Willi syndrome. Journal of Endocrinological Investigation, 2021, 44, 2261-2271.	1.8	11
9	The Myokine Irisin Promotes Osteogenic Differentiation of Dental Bud-Derived MSCs. Biology, 2021, 10, 295.	1.3	20
10	The Novel Role of PGC1Î± in Bone Metabolism. International Journal of Molecular Sciences, 2021, 22, 4670.	1.8	12
11	FNDC5/irisin is expressed and regulated differently in human periodontal ligament cells, dental pulp stem cells and osteoblasts. Archives of Oral Biology, 2021, 124, 105061.	0.8	9
12	Mechanisms of altered bone remodeling in children with type 1 diabetes. World Journal of Diabetes, 2021, 12, 997-1009.	1.3	8
13	The effect of Irisin on bone cells in vivo and in vitro. Biochemical Society Transactions, 2021, 49, 477-484.	1.6	24
14	Systemic Administration of Recombinant Irisin Accelerates Fracture Healing in Mice. International Journal of Molecular Sciences, 2021, 22, 10863.	1.8	22
15	Muscle-Derived Soluble Mediators Regulating Bone. , 2020, , 356-361.		0
16	Irisin promotes growth, migration and matrix formation in human periodontal ligament cells. Archives of Oral Biology, 2020, 111, 104635.	0.8	20
17	LIGHT/TNFSF14 Promotes Osteolytic Bone Metastases in Nonâ€small Cell Lung Cancer Patients. Journal of Bone and Mineral Research, 2020, 35, 671-680.	3.1	31
18	Irisin Prevents Disuseâ€Induced Osteocyte Apoptosis. Journal of Bone and Mineral Research, 2020, 35, 766-775.	3.1	82

#	Article	IF	Citations
19	Irisin prevents microgravityâ€induced impairment of osteoblast differentiation in vitro during the space flight CRSâ€14 mission. FASEB Journal, 2020, 34, 10096-10106.	0.2	38
20	Myokines and Osteokines in the Pathogenesis of Muscle and Bone Diseases. Current Osteoporosis Reports, 2020, 18, 401-407.	1.5	28
21	Shedding â€œLIGHTâ€•on the Link between Bone and Fat in Obese Children and Adolescents. International Journal of Molecular Sciences, 2020, 21, 4739.	1.8	6
22	LIGHT/TNFSF14 regulates estrogen deficiencyâ€induced bone loss. Journal of Pathology, 2020, 250, 440-451.	2.1	15
23	Novel insights in health-promoting properties of sweet cherries. Journal of Functional Foods, 2020, 69, 103945.	1.6	45
24	Irisin Correlates Positively With BMD in a Cohort of Older Adult Patients and Downregulates the Senescent Marker p21 in Osteoblasts. Journal of Bone and Mineral Research, 2020, 36, 305-314.	3.1	42
25	In Reply to the Letter to the Editor: Involvement of Irisin in Age-Related Osteoporosis and Its Inhibitory Effect on the Senescent Marker p21 in Osteoblasts. Journal of Bone and Mineral Research, 2020, 36, 1420-1421.	3.1	3
26	Irisin serum levels are positively correlated with bone mineral status in a population of healthy children. Pediatric Research, 2019, 85, 484-488.	1.1	45
27	A Novel Interplay Between Irisin and PTH: From Basic Studies to Clinical Evidence in Hyperparathyroidism. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 3088-3096.	1.8	41
28	Mechanisms Involved in Childhood Obesity-Related Bone Fragility. Frontiers in Endocrinology, 2019, 10, 269.	1.5	43
29	Effects of Sweet Cherry Polyphenols on Enhanced Osteoclastogenesis Associated With Childhood Obesity. Frontiers in Immunology, 2019, 10, 1001.	2.2	24
30	Irisin and Bone: From Preclinical Studies to the Evaluation of Its Circulating Levels in Different Populations of Human Subjects. Cells, 2019, 8, 451.	1.8	41
31	Metabolic Bone Disease of Prematurity: Diagnosis and Management. Frontiers in Pediatrics, 2019, 7, 143.	0.9	86
32	An update on the role of RANKLâ€“RANK/osteoprotegerin and WNT-ÃŸ-catenin signaling pathways in pediatric diseases. World Journal of Pediatrics, 2019, 15, 4-11.	0.8	29
33	Stemness genes expression in naÃ¯ve vs. osteodifferentiated human dental-derived stem cells. European Review for Medical and Pharmacological Sciences, 2019, 23, 2916-2923.	0.5	12
34	High irisin levels are associated with better glycemic control and bone health in children with Type 1 diabetes. Diabetes Research and Clinical Practice, 2018, 141, 10-17.	1.1	60
35	Mechanisms of Enhanced Osteoclastogenesis in Alkaptonuria. American Journal of Pathology, 2018, 188, 1059-1068.	1.9	20
36	Myokineâ€”Irisinâ€”and Its Effects Linking Bone and Muscle Function. Clinical Reviews in Bone and Mineral Metabolism, 2018, 16, 16-21.	1.3	3

#	Article	IF	Citations
37	Inflammation induces osteoclast differentiation from peripheral mononuclear cells in chronic kidney disease patients: crosstalk between the immune and bone systems. Nephrology Dialysis Transplantation, 2018, 33, 65-75.	0.4	41
38	Impairment of Bone Remodeling in LIGHT/TNFSF14-Deficient Mice. Journal of Bone and Mineral Research, 2018, 33, 704-719.	3.1	16
39	Monoclonal antibodies for treating osteoporosis. Expert Opinion on Biological Therapy, 2018, 18, 149-157.	1.4	45
40	High expression of TRAIL by osteoblastic differentiated dental pulp stem cells affects myeloma cell viability. Oncology Reports, 2018, 39, 2031-2039.	1.2	13
41	LIGHT/TNFSF14 as a New Biomarker of Bone Disease in Multiple Myeloma Patients Experiencing Therapeutic Regimens. Frontiers in Immunology, 2018, 9, 2459.	2.2	20
42	Anatomy and Physiology of Skeletal Tissue: The Bone Cells. , 2018, , 1-23.		2
43	Analysis of Circulating Mediators of Bone Remodeling in Praderâ€“Willi Syndrome. Calcified Tissue International, 2018, 102, 635-643.	1.5	19
44	Vitamin D Promotes MSC Osteogenic Differentiation Stimulating Cell Adhesion and Î±VÎ²3 Expression. Stem Cells International, 2018, 2018, 1-9.	1.2	28
45	Polydatin, Natural Precursor of Resveratrol, Promotes Osteogenic Differentiation of Mesenchymal Stem Cells. International Journal of Medical Sciences, 2018, 15, 944-952.	1.1	43
46	Irisin Serum Levels in Metabolic Syndrome Patients Treated with Three Different Diets: A Post-Hoc Analysis from a Randomized Controlled Clinical Trial. Nutrients, 2018, 10, 844.	1.7	23
47	Deletion of the Transcription Factor PGC-1Î± in Mice Negatively Regulates Bone Mass. Calcified Tissue International, 2018, 103, 638-652.	1.5	17
48	Irisin and musculoskeletal health. Annals of the New York Academy of Sciences, 2017, 1402, 5-9.	1.8	112
49	Sclerostin stimulates angiogenesis in human endothelial cells. Bone, 2017, 101, 26-36.	1.4	20
50	Mechanisms of Altered Bone Remodeling in Multiple Myeloma. Clinical Reviews in Bone and Mineral Metabolism, 2017, 15, 151-161.	1.3	1
51	Irisin prevents and restores bone loss and muscle atrophy in hind-limb suspended mice. Scientific Reports, 2017, 7, 2811.	1.6	221
52	High Sclerostin and Dickkopf-1 (DKK-1) Serum Levels in Children and Adolescents With Type 1 Diabetes Mellitus. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 1174-1181.	1.8	67
53	NURR1 Downregulation Favors Osteoblastic Differentiation of MSCs. Stem Cells International, 2017, 2017, 1-10.	1.2	19
54	Bone Regeneration Induced by Bone Porcine Block with Bone Marrow Stromal Stem Cells in a Minipig Model of Mandibular â€œCritical Sizeâ€•Defect. Stem Cells International, 2017, 2017, 1-9.	1.2	31

#	Article	IF	Citations
55	Irisin levels correlate with bone mineral density in soccer players. Journal of Biological Regulators and Homeostatic Agents, 2017, 31, 21-28.	0.7	27
56	Vitamin D Effects on Osteoblastic Differentiation of Mesenchymal Stem Cells from Dental Tissues. Stem Cells International, 2016, 2016, 1-9.	1.2	47
57	Bone Fragility in Turner Syndrome: Mechanisms and Prevention Strategies. Frontiers in Endocrinology, 2016, 7, 34.	1.5	35
58	Crosstalk Between Muscle and Bone Via the Muscle-Myokine Irisin. Current Osteoporosis Reports, 2016, 14, 132-137.	1.5	56
59	High serum sclerostin levels in children with haemophilia A. British Journal of Haematology, 2016, 172, 293-295.	1.2	24
60	Impaired bone remodeling in children with osteogenesis imperfecta treated and untreated with bisphosphonates: the role of DKK1, RANKL, and TNF-Î±. Osteoporosis International, 2016, 27, 2355-2365.	1.3	52
61	Functions of vasopressin and oxytocin in bone mass regulation. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 164-169.	3.3	54
62	The effects of bone pÃ¢tÃ© on human osteoblasts cell cultures. European Archives of Oto-Rhino-Laryngology, 2016, 273, 1399-1404.	0.8	1
63	Human Myeloma Cell Lines Induce Osteoblast Downregulation of CD99 Which Is Involved in Osteoblast Formation and Activity. Journal of Immunology Research, 2015, 2015, 1-13.	0.9	6
64	Skeleton and Glucose Metabolism: A Bone-Pancreas Loop. International Journal of Endocrinology, 2015, 2015, 1-7.	0.6	23
65	Role of Irisin on the boneâ€“muscle functional unit. BoneKEy Reports, 2015, 4, 765.	2.7	47
66	Metabolic syndrome in childhood leukemia survivors: a meta-analysis. Endocrine, 2015, 49, 353-360.	1.1	14
67	Mechanisms of enhanced osteoclastogenesis in girls and young women with Turner's Syndrome. Bone, 2015, 81, 228-236.	1.4	31
68	Evaluation of impact of steroid replacement treatment on bone health in children with 21-hydroxylase deficiency. Endocrine, 2015, 48, 995-1000.	1.1	10
69	Osteogenic differentiation of mesenchymal stem cells from dental bud: Role of integrins and cadherins. Stem Cell Research, 2015, 15, 618-628.	0.3	70
70	The myokine irisin increases cortical bone mass. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 12157-12162.	3.3	372
71	CELLULAR MECHANISMS OF BONE REGENERATION: ROLE OF WNT-1 IN BONE-MUSCLE INTERACTION DURING PHYSICAL ACTIVITY39. Journal of Biological Regulators and Homeostatic Agents, 2015, 29, 39-45.	0.7	10
72	Osteoclastogenic Potential of Peripheral Blood Mononuclear Cells in Cleidocranial Dysplasia. International Journal of Medical Sciences, 2014, 11, 356-364.	1.1	5

#	Article	IF	Citations
73	Osteoporosis and obesity: Role of Wnt pathway in human and murine models. World Journal of Orthopedics, 2014, 5, 242.	0.8	56
74	Irisin Enhances Osteoblast DifferentiationIn Vitro. International Journal of Endocrinology, 2014, 2014, 1-8.	0.6	161
75	Treatment of osteoporosis in children with glucocorticoid-treated diseases. Expert Review of Endocrinology and Metabolism, 2014, 9, 525-534.	1.2	4
76	Osteoblast regulation via ligand-activated nuclear trafficking of the oxytocin receptor. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 16502-16507.	3.3	63
77	CD99 Drives Terminal Differentiation of Osteosarcoma Cells by Acting as a Spatial Regulator of ERK 1/2. Journal of Bone and Mineral Research, 2014, 29, 1295-1309.	3.1	37
78	Bone Cells. , 2014, , 3-13.		3
79	Experimental Model for Studying the Involvement of Regulatory Cytotoxic T Cells in Bone Resorption. Methods in Molecular Biology, 2014, 1186, 269-281.	0.4	2
80	LIGHT/TNFSF14 increases osteoclastogenesis and decreases osteoblastogenesis in multiple myeloma-bone disease. Oncotarget, 2014, 5, 12950-12967.	0.8	52
81	Osteotropic Cancers: From Primary Tumor to Bone. Clinical Reviews in Bone and Mineral Metabolism, 2013, 11, 94-102.	1.3	5
82	Aortic valvular interstitial cells apoptosis and calcification are mediated by TNF-related apoptosis-inducing ligand. International Journal of Cardiology, 2013, 169, 296-304.	0.8	77
83	Osteoblasts Display Different Responsiveness to TRAIL-Induced Apoptosis During Their Differentiation Process. Cell Biochemistry and Biophysics, 2013, 67, 1127-1136.	0.9	21
84	High dickkopf-1 levels in sera and leukocytes from children with 21-hydroxylase deficiency on chronic glucocorticoid treatment. American Journal of Physiology - Endocrinology and Metabolism, 2013, 304, E546-E554.	1.8	41
85	Biological Characteristics of Dental Stem Cells for Tissue Engineering. Key Engineering Materials, 2013, 541, 51-59.	0.4	4
86	Regulation of bone remodeling by vasopressin explains the bone loss in hyponatremia. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 18644-18649.	3.3	120
87	Activation of the receptor activator of the nuclear factor-ÂB ligand pathway during coronary bypass surgery: comparison between on- and off-pump coronary artery bypass surgery procedures. European Journal of Cardio-thoracic Surgery, 2013, 44, e141-e147.	0.6	10
88	Glucocorticoid-Induced Osteoporosis in Children with 21-Hydroxylase Deficiency. BioMed Research International, 2013, 2013, 1-8.	0.9	39
89	Cellular Mechanisms of Multiple Myeloma Bone Disease. Clinical and Developmental Immunology, 2013, 2013, 1-11.	3.3	52
90	The Role of TNF-Î±and TNF Superfamily Members in the Pathogenesis of Calcific Aortic Valvular Disease. Scientific World Journal, The, 2013, 2013, 1-10.	0.8	31

#	Article	IF	Citations
91	Periodontal Disease: Linking the Primary Inflammation to Bone Loss. Clinical and Developmental Immunology, 2013, 2013, 1-7.	3.3	215
92	Bone Marrow Oxytocin Mediates the Anabolic Action of Estrogen on the Skeleton. Journal of Biological Chemistry, 2012, 287, 29159-29167.	1.6	66
93	Genotypeâ€“phenotype correlation in Juvenile Paget disease: role of molecular alterations of the TNFRSF11B gene. Endocrine, 2012, 42, 266-271.	1.1	23
94	Osteogenic Differentiation of Dental Follicle Stem Cells. International Journal of Medical Sciences, 2012, 9, 480-487.	1.1	65
95	Regulated production of the pituitary hormone oxytocin from murine and human osteoblasts. Biochemical and Biophysical Research Communications, 2011, 411, 512-515.	1.0	47
96	TRAIL effect on osteoclast formation in physiological and pathological conditions. Frontiers in Bioscience - Elite, 2011, E3, 1154-1161.	0.9	14
97	Sclerostin is overexpressed by plasma cells from multiple myeloma patients. Annals of the New York Academy of Sciences, 2011, 1237, 19-23.	1.8	77
98	Dental pulp stem cells: osteogenic differentiation and gene expression. Annals of the New York Academy of Sciences, 2011, 1237, 47-52.	1.8	82
99	FT-IR microscopic analysis on human dental pulp stem cells. Vibrational Spectroscopy, 2011, 57, 30-30.	1.2	20
100	Osteoclastogenesis and arthritis. Clinical and Experimental Medicine, 2011, 11, 137-145.	1.9	52
101	Myeloma cells suppress osteoblasts through sclerostin secretion. Blood Cancer Journal, 2011, 1, e27-e27.	2.8	113
102	The formation of osteoclasts in multiple myeloma bone disease patients involves the secretion of soluble decoy receptor 3. Annals of the New York Academy of Sciences, 2010, 1192, 298-302.	1.8	14
103	Immunoregulation of Osteoclast Differentiation in Multiple Myeloma Bone Disease. , 2010, , 67-75.		0
104	Myeloma Cells Induce Osteoblast Suppression through Sclerostin Secretion. Blood, 2010, 116, 2961-2961.	0.6	4
105	Osteogenic properties of human dental pulp stem cells. Journal of Biological Regulators and Homeostatic Agents, 2010, 24, 167-75.	0.7	29
106	Oxytocin is an anabolic bone hormone. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 7149-7154.	3.3	223
107	Microgravity during spaceflight directly affects in vitro osteoclastogenesis and bone resorption. FASEB Journal, 2009, 23, 2549-2554.	0.2	106
108	Osteoclastogenesis in Children with 21-Hydroxylase Deficiency on Long-Term Glucocorticoid Therapy: The Role of Receptor Activator of Nuclear Factor-ÎºB Ligand/Osteoprotegerin Imbalance. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 2269-2276.	1.8	44

#	Article	IF	Citations
109	Osteoblast Apoptosis in Periodontal Disease: Role of TNF-Related Apoptosis-Inducing Ligand. International Journal of Immunopathology and Pharmacology, 2009, 22, 95-103.	1.0	40
110	Immunomodulation of Multiple Myeloma Bone Disease. Clinical Reviews in Bone and Mineral Metabolism, 2009, 7, 293-300.	1.3	4
111	Normal and osteoporotic human osteoblast behaviour after 1,25-dihydroxy-vitamin D3 stimulation. Rheumatology International, 2009, 29, 667-672.	1.5	10
112	Soluble decoy receptor 3 modulates the survival and formation of osteoclasts from multiple myeloma bone disease patients. Leukemia, 2009, 23, 2139-2146.	3.3	38
113	l-Carnitine Fumarate and Isovaleryl-l-Carnitine Fumarate Accelerate the Recovery of Bone Volume/Total Volume Ratio after Experimetally Induced Osteoporosis in Pregnant Mice. Calcified Tissue International, 2008, 82, 221-228.	1.5	19
114	In Vitro Stem Cell Cultures from Human Dental Pulp and Periodontal Ligament: New Prospects in Dentistry. International Journal of Immunopathology and Pharmacology, 2007, 20, 9-16.	1.0	46
115	Lymphocytes and synovial fluid fibroblasts support osteoclastogenesis through RANKL, TNFÎ±, and IL-7 in anin vitromodel derived from human psoriatic arthritis. Journal of Pathology, 2007, 212, 47-55.	2.1	86
116	ILâ€7 Modulates Osteoclastogenesis in Patients Affected by Solid Tumors. Annals of the New York Academy of Sciences, 2007, 1117, 377-384.	1.8	20
117	TRAIL Is Involved in Human Osteoclast Apoptosis. Annals of the New York Academy of Sciences, 2007, 1116, 316-322.	1.8	12
118	Synovial Fluid Fibroblasts and Lymphocytes Support the Osteoclastogenesis in Human Psoriatic Arthritis. Annals of the New York Academy of Sciences, 2007, 1117, 159-164.	1.8	10
119	The death receptor DR5 is involved in TRAIL-mediated human osteoclast apoptosis. Apoptosis: an International Journal on Programmed Cell Death, 2007, 12, 1623-1632.	2.2	53
120	Alteration of activity and survival of osteoblasts obtained from human periodontitis patients: role of TRAIL. Journal of Biological Regulators and Homeostatic Agents, 2007, 21, 105-14.	0.7	29
121	IL-7 Up-Regulates TNF-Î±-Dependent Osteoclastogenesis in Patients Affected by Solid Tumor. PLoS ONE, 2006, 1, e124.	1.1	62
122	The Role of OPG/TRAIL Complex in Multiple Myeloma: The OPG/TRAIL Complex in an In Vitro Osteoclastogenesis Model Derived From Human Multiple Myeloma-Bone Disease. Annals of the New York Academy of Sciences, 2006, 1068, 334-340.	1.8	14
123	Myeloma cells block RUNX2/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation. Blood, 2005, 106, 2472-2483.	0.6	289
124	Gorham-Stout Syndrome: A Monocyte-Mediated Cytokine Propelled Disease. Journal of Bone and Mineral Research, 2005, 21, 207-218.	3.1	64
125	L-Carnitine and Isovaleryl L-Carnitine Fumarate Positively Affect Human Osteoblast Proliferation and Differentiation In Vitro. Calcified Tissue International, 2005, 76, 458-465.	1.5	39
126	Neridronate and human osteoblasts in normal, osteoporotic and osteoarthritic subjects. Clinical Rheumatology, 2005, 24, 527-534.	1.0	24

#	Article	IF	Citations
127	Mechanisms of spontaneous osteoclastogenesis in cancer with bone involvement. FASEB Journal, 2005, 19, 1-24.	0.2	88
128	T Cells Support Osteoclastogenesis in an In Vitro Model Derived From Human Periodontitis Patients. Journal of Periodontology, 2005, 76, 1675-1680.	1.7	78
129	Interleukin-7 production by B lymphocytes affects the T cell-dependent osteoclast formation in an in vitro model derived from human periodontitis patients. International Journal of Immunopathology and Pharmacology, 2005, 18, 13-9.	1.0	18
130	Dehydroepiandrosterone Stimulates Glucose Uptake in Human and Murine Adipocytes by Inducing GLUT1 and GLUT4 Translocation to the Plasma Membrane. Diabetes, 2004, 53, 41-52.	0.3	102
131	Osteocalcin synthesis by human osteoblasts from normal and osteoarthritic bone after vitamin D3 stimulation. Clinical Rheumatology, 2004, 23, 490-495.	1.0	31
132	Proteolytic imbalance is reversed after therapeutic surgery in breast cancer patients. International Journal of Cancer, 2004, 109, 782-785.	2.3	31
133	T cells support osteoclastogenesis in an in vitro model derived from human multiple myeloma bone disease: the role of the OPG/TRAIL interaction. Blood, 2004, 104, 3722-3730.	0.6	138
134	Human osteoclasts express oxytocin receptor. Biochemical and Biophysical Research Communications, 2002, 297, 442-445.	1.0	58
135	Rat Hindlimb Unloading by Tail Suspension Reduces Osteoblast Differentiation, Induces IL-6 Secretion, and Increases Bone Resorption in Ex Vivo Cultures. Calcified Tissue International, 2002, 70, 176-185.	1.5	54
136	Localization and possible role of two different alpha v beta 3 integrin conformations in resting and resorbing osteoclasts. Journal of Cell Science, 2002, 115, 2919-2929.	1.2	63
137	Localization and possible role of two different alpha v beta 3 integrin conformations in resting and resorbing osteoclasts. Journal of Cell Science, 2002, 115, 2919-29.	1.2	52
138	HGF and M-CSF modulate adhesion of MDA-231 breast cancer cell by increasing osteopontin secretion. Journal of Biological Regulators and Homeostatic Agents, 2002, 16, 190-5.	0.7	4
139	Breast Cancer Cell Line MDA-231 Stimulates Osteoclastogenesis and Bone Resorption in Human Osteoclasts. Biochemical and Biophysical Research Communications, 2000, 270, 1097-1100.	1.0	57
140	Hydroxyapatite coated with hepatocyte growth factor (HGF) stimulates human osteoblasts in vitro. Journal of Bone and Joint Surgery: British Volume, 2000, 82-B, 457-460.	3.4	10
141	Hydroxyapatite coated with heaptocyte growth factor (HGF) stimulates human osteoblasts in vitro. Journal of Bone and Joint Surgery: British Volume, 2000, 82, 457-60.	3.4	89
142	Hydroxyapatite coated with insulin-like growth factor 1 (IGF1) stimulates human osteoblast activity in vitro. Acta Orthopaedica, 1999, 70, 217-220.	1.4	18
143	Expression of estrogen receptor-alpha in cells of the osteoclastic lineage. Histochemistry and Cell Biology, 1999, 111, 125-133.	0.8	59
144	Response of Human Osteoblasts to Polymethylmetacrylate In Vitro. Calcified Tissue International, 1998, 62, 362-365.	1.5	57

#	Article	IF	Citations
145	Alendronate Reduces Adhesion of Human Osteoclast-like Cells to Bone and Bone Protein-Coated Surfaces. Calcified Tissue International, 1998, 63, 230-235.	1.5	81
146	In vitro toxicity of N3-methyl-5â€²-deoxy-5-fluorouridine, a novel metabolite of doxifluridine: a bioanalytical investigation. Journal of Pharmaceutical and Biomedical Analysis, 1998, 17, 11-16.	1.4	11
147	Activation of Î±vÎ²3Integrin on Human Osteoclast-like Cells Stimulates Adhesion and Migration in Response to Osteopontin. Biochemical and Biophysical Research Communications, 1998, 249, 522-525.	1.0	57
148	The Osteoclast Cytoskeleton. Advances in Organ Biology, 1998, 5, 347-357.	0.1	0
149	Retinoic Acid Induces Cell Proliferation and Modulates Gelatinases Activity in Human Osteoclast-like Cell Lines. Biochemical and Biophysical Research Communications, 1996, 227, 47-52.	1.0	13
150	Hepatocyte growth factor is a coupling factor for osteoclasts and osteoblasts in vitro.. Proceedings of the National Academy of Sciences of the United States of America, 1996, 93, 7644-7648.	3.3	202
151	Human osteoclast-like cells selectively recognize laminin isoforms, an event that induces migration and activates Ca2+ mediated signals. Journal of Cell Science, 1996, 109, 1527-1535.	1.2	16
152	Biomaterials in orthopaedic surgery: effects of different hydroxyapatites and demineralized bone matrix on proliferation rate and bone matrix synthesis by human osteoblasts. Biomaterials, 1995, 16, 397-402.	5.7	95
153	Human Osteoclast-Like Cells from Giant Cell Tumors of Bone: A New Tool for Investigating Bone Resorption and Osteoclast Biology. Calcified Tissue International, 1995, 56, S24-S24.	1.5	5
154	Extracellular Ca2+ sensing is modulated by pH in human osteoclast-like cells in vitro. American Journal of Physiology - Cell Physiology, 1994, 267, C961-C968.	2.1	25
155	Osteocalcin induces chemotaxis, secretion of matrix proteins, and calcium-mediated intracellular signaling in human osteoclast-like cells.. Journal of Cell Biology, 1994, 127, 1149-1158.	2.3	168
156	Adhesion Properties and Integrin Expression of Cultured Human Osteoclast-like Cells. Experimental Cell Research, 1994, 212, 209-218.	1.2	47
157	New model for bone resorption study in vitro: Human osteoclast-like cells from giant cell tumors of bone. Journal of Bone and Mineral Research, 1994, 9, 1013-1020.	3.1	42
158	Binding of osteopontin to the osteoclast integrin Î±vÎ²3. Osteoporosis International, 1993, 3, 132-135.	1.3	35
159	Immediate cell signal by bone-related peptides in human osteoclast-like cells. American Journal of Physiology - Cell Physiology, 1993, 265, C1289-C1297.	2.1	46
160	Osteoblast-osteoclast relationships in bone resorption: Osteoblasts enhance osteoclast activity in a serum-free co-culture system. Biochemical and Biophysical Research Communications, 1991, 179, 634-640.	1.0	29
161	Effects of Calcium-phosphate-based Materials on Proliferation and Alkaline Phosphatase Activity of Newborn Rat Periosteal Cells in vitro. Journal of Dental Research, 1991, 70, 997-1001.	2.5	18
162	Recognition of osteopontin and related peptides by an alpha v beta 3 integrin stimulates immediate cell signals in osteoclasts.. Journal of Biological Chemistry, 1991, 266, 20369-20374.	1.6	345

#	Article	IF	Citations
163	Recognition of osteopontin and related peptides by an alpha v beta 3 integrin stimulates immediate cell signals in osteoclasts. Journal of Biological Chemistry, 1991, 266, 20369-74.	1.6	290
164	Immunocytochemical distribution of extracellular matrix receptors in human osteoclasts: A Î²3 integrin is colocalized with vinculin and talin in the podosomes of osteoclastoma giant cells. Experimental Cell Research, 1989, 182, 645-652.	1.2	197
165	Extracellular protons acidify osteoclasts, reduce cytosolic calcium, and promote expression of cell-matrix attachment structures.. Journal of Clinical Investigation, 1989, 84, 773-780.	3.9	138